The global diabetic ketoacidosis treatment market size is expected to reach US$ 3.5 Billion in 2022 and exhibit growth at a CAGR of 5.7% in the forecast period from 2022 to 2032. It is anticipated to surpass US$ 6.8 Billion in 2032. The rising prevalence of diabetes, especially type 1 diabetes globally is a major factor that is set to propel the demand for diabetic ketoacidosis treatment options.
| Report Attribute | Details |
|---|---|
| Diabetic Ketoacidosis Treatment Market Estimated Base Year Value (2021) | US$ 2.1 Billion |
| Diabetic Ketoacidosis Treatment Market Expected Market Value (2022) | US$ 3.5 Billion |
| Diabetic Ketoacidosis Treatment Market Anticipated Forecast Value (2032) | US$ 6.8 Billion |
| Diabetic Ketoacidosis Treatment Market Projected Growth Rate (2022 to 2032) | 5.7% CAGR |
Diabetic ketoacidosis is a life-threatening complication that occurs with diabetes. It is a very common condition in patients suffering from type 1 diabetes. It leads to the buildup of acids in the patient’s blood.
Headache, dry mouth, frequent peeing, fatigue, less alertness, nausea, belly pain, and muscle aches are some of the first symptoms of this condition. It happens when an individual’s body doesn’t have adequate insulin.
When the cells are incapable of using sugar in the blood for generating energy, they start using fuel and fats instead. The burning of fats often creates ketones, which can eventually change the blood’s chemical balance and disrupt the entire system.
The increasing focus of many manufacturers on the development of cost-effective treatment options for this condition is likely to spur the market. In January 2020, for instance, Eli Lilly and Company announced that it is planning to launch two new cost-saving insulin solutions. Similar other product launches are expected to bode well for the market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The high demand for more efficient technologies and drugs for the treatment and management of diabetic ketoacidosis is projected to bolster the market in the evaluation period. The increasing awareness about the availability of various unique products for the treatment of this condition is another crucial factor that is anticipated to bode well for the diabetic ketoacidosis treatment market growth.
The rising number of several pharmaceutical companies in both developed and developing countries is also likely to drive the market. The rapid adoption of novel treatment facilities by numerous medium and small healthcare centers, as well as hospitals is estimated to spur the growth.
The lack of advanced treatment options and awareness about diabetic ketoacidosis in emerging economies may obstruct the market in the assessment period. Adverse side effects associated with the treatment of this condition can also hamper the graowth.
Adjustment of the blood sugar level at a rapid pace by using insulin and fluids can cause swelling in the brain. At the same time, it can lead to impair activities of the nervous system, muscles, and heart, as well as a drop in potassium level in the blood.
Besides, the requirement of constant monitoring of insulin levels and the unavailability of skilled healthcare professionals in remote areas are anticipated to negatively affect the sales of diabetic ketoacidosis treatment options. The limited availability of innovative facilities in multiple healthcare centers and hospitals can hinder the market.
Principal Consultant
The rising cases of diabetes among the population in Canada and the U.S. are projected to fuel the North America diabetic ketoacidosis treatment market share. According to the Centers for Disease Control and Prevention (CDC), in the U.S., nearly 37.3 million people have diabetes and 8.5 million adults are undiagnosed. These numbers are estimated to surge in the future years, thereby driving the North America market.
The presence of favorable reimbursement scenarios and the increasing awareness regarding the early diagnosis of this condition are likely to accelerate the market. The availability of cutting-edge treatment options and the entrance of several renowned companies in this region are also set to propel the market.
Asia Pacific is expected to remain in the second position and exhibit a steady diabetic ketoacidosis treatment market growth. The rising incidence of type 1 diabetes and the surging adoption of sedentary lifestyles are projected to augur well for the market.
The high geriatric population and the increasing adoption of effective strategies by leading companies based in China and India are some of the other crucial factors that are likely to aid the growth. The surging usage of insulin therapy backed by the ongoing advancement in the field of insulin delivery technique is another factor that is likely to augment the regional market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the prominent companies operating in the global diabetic ketoacidosis treatment market include Merck & Co., Inc., Novo Nordisk A/S, Eli Lilly and Company, Biocon Limited, Wockhardt Ltd., Sanofi S.A., Bristol Myers Squibb, Tonghua Dongbao Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Oramed Pharmaceuticals Inc., and Pfizer Inc. among others.
Some of the leading players are engaging in partnerships and collaborations with renowned companies to co-develop new treatment options and gain fast track approvals from regulatory bodies. Meanwhile, a few other players are increasingly focusing on broadening their existing product portfolios and expanding their geographic presence to fulfill the high unmet demand worldwide.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.7% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment Type, Application, End User, Region |
| Regions Covered | North America; Latin America; Western Europe; Easter Europe; APEJ; Japan; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
| Key Companies Profiled | Merck & Co., Inc.; Novo Nordisk A/S; Eli Lilly and Company; Biocon Limited; Wockhardt Ltd.; Sanofi S.A.; Bristol Myers Squibb; Tonghua Dongbao Pharmaceutical Co., Ltd.; GlaxoSmithKline plc; Oramed Pharmaceuticals Inc.; Pfizer Inc. |
| Customization | Available Upon Request |
The global diabetic ketoacidosis treatment market is estimated to exceed US$ 6.8 Billion by 2032.
North America is expected to dominate the diabetic ketoacidosis treatment market.
Merck & Co., Inc., Novo Nordisk A/S, Eli Lilly and Company, Biocon Limited, Wockhardt Ltd., Sanofi S.A., and Bristol Myers Squibb are some of the leading companies in the diabetic ketoacidosis treatment market.
Explore Healthcare Insights
View Reports
Diabetic Ketoacidosis Treatment Market
